CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 5 enrolled
Drug / intervention
Eszopiclone +1 moredrug
Likely dose
Eszopiclone 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00822679
NCT00822679Phase 4Completed
CompareCT.gov

Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome

University of Arizona·interventional·Posted Jan 14, 2009·Updated Dec 20, 2016

In Brief

A Phase 4 clinical trial evaluating Eszopiclone and Placebo for Acute Coronary Syndrome and Sleep Disorder. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purpose of the study is to examine the effects of Eszopiclone, a sleep aid, on inflammatory mediators and coagulability in patients with a recent myocardial infarction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome, Sleep Disorder
CountriesUnited States
CollaboratorsSumitomo Pharma America, Inc., Southern Arizona VA Health Care System

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 14, 2009
Enrollment StartOct 1, 2007
Primary CompletionAug 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.5 years ago

Interventions

Eszopiclonedrug

Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.

Placeboother

Subjects are given placebo for 3 consecutive nights